Managers / Q3 2020
Puissance Capital Management LP
CIK 0001658437 · 950 THIRD AVENUE, 25TH FLOOR, NEW YORK, NY, 10022 · 212-878-3700
Summary
Puissance Capital Management LP reported $17M in U.S.-listed holdings across 5 positions for Q3 2020.
The portfolio is heavily concentrated: Bellerophon Therapeutics alone accounts for 67.7% of reported value.
Compared with Q2 2020, the fund opened 2 new positions and exited 1.
Portfolio Metrics
Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.
Reported Value by Quarter
Portfolio Composition
- Common Stock · 100.0% · $17M
Quarter-over-Quarter Changes full breakdown →
vs Q2 2020 (amended baseline)
| Issuer | Move | Share Δ | Shares now | Value Δ | Value now |
|---|---|---|---|---|---|
| SCYNEXIS INC | NEW | +311.1K | 311.1K | +$1M | $1M |
| KDMNKADMON HLDGS INC | NEW | +100.2K | 100.2K | +$393,000 | $393,000 |
| SCYNEXIS INC | SOLD OUT | −3.11M | 0 | −$2M | $0 |
| EKSO BIONICS HLDGS INC | HELD | +0 | 774.4K | −$3M | $4M |
| BELLEROPHON THERAPEUTICS INC | HELD | +0 | 1.15M | −$3M | $12M |
| CRVSCORVUS PHARMACEUTICALS INC | HELD | +0 | 38.0K | +$49,000 | $152,000 |
Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.
Holdings — Q3 2020
| # | Issuer | Class | % Portfolio | Value ↓ | Shares |
|---|---|---|---|---|---|
| 1 | BELLEROPHON THERAPEUTICS INC | COM NEW | 67.74% | $12M | 1.15M |
| 2 | EKSO BIONICS HLDGS INC | COM | 21.21% | $4M | 774.4K |
| 3 | SCYNEXIS INC | COM NEW | 7.91% | $1M | 311.1K |
| 4 | KDMNKADMON HLDGS INChistory → | COM | 2.27% | $393,000 | 100.2K |
| 5 | CRVSCORVUS PHARMACEUTICALS INC | COM | 0.88% | $152,000 | 38.0K |
Filing History
| Quarter | Reported Value | Positions | Filed | Type | Links |
|---|---|---|---|---|---|
| Q3 2020 | $17M | 5 | Nov 12, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q2 2020 | $23M | 4 | Aug 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q1 2020 | $9M | 6 | May 15, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q4 2019 | $40M | 6 | Feb 14, 2020 | 13F-HR | changes · EDGAR ↗ |
| Q3 2019 | $45M | 7 | Nov 14, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q2 2019 | $102M | 7 | Aug 13, 2019 | 13F-HR | changes · EDGAR ↗ |
| Q1 2019 | $123M | 6 | May 14, 2019 | 13F-HR | changes · EDGAR ↗ |
13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.